Several brokerages have updated their recommendations and price targets on shares of Illumina (NASDAQ: ILMN) in the last few weeks:

  • 8/9/2017 – Illumina was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $209.78 price target on the stock.
  • 8/9/2017 – Illumina had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $150.00 price target on the stock.
  • 8/7/2017 – Illumina was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/7/2017 – Illumina was upgraded by analysts at Canaccord Genuity from a “hold” rating to a “buy” rating. They now have a $215.00 price target on the stock, up previously from $170.00. They wrote, “Shipments to China grew +16% and we believe China is likely to be a double-digit grower for ILMN over the next several years, driven by the Chinese Precision Medicine Initiative,”
  • 8/4/2017 – Illumina was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Illumina exited the second quarter on a solid note, with both earnings and revenues beating the Zacks Consensus Estimate. The top line was strong on new product launches including the VeriSeq NIPT Solution in Europe and the strength in NovaSeq. Outside the U.S., the rate of NIPT adoption is increasing. In this regard to note, over the last three months, Illumina was trading above the broader industry. The company’s raised guidance is encouraging indicating this bullish trend to continue in the coming period. We are currently looking forward to the performance of the Extended RAS Panel that is slated for launch in the third quarter. We are also looking forward to GRAIL, Illumina’s venture in the cancer screening market. On the flip side, weak margins owing to NovaSeq launch, higher array services revenues and product mix within sequencing consumables will continue to act as deterrents. Also, NIH funding issue and a tough competitive landscap”
  • 8/2/2017 – Illumina was downgraded by analysts at Vetr from a “strong-buy” rating to a “hold” rating. They now have a $202.18 price target on the stock.
  • 8/2/2017 – Illumina had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $200.00 price target on the stock.
  • 8/2/2017 – Illumina was upgraded by analysts at First Analysis from an “underweight” rating to an “equal weight” rating. They now have a $176.00 price target on the stock.
  • 8/2/2017 – Illumina had its “overweight” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $250.00 price target on the stock.
  • 8/1/2017 – Illumina was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 7/28/2017 – Illumina was given a new $175.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 7/27/2017 – Illumina was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $195.00 price target on the stock. According to Zacks, “Illumina has witnessed robust revenue growth on account of consistent improvement in sequencing consumables and strong demand of microarrays in the last reported quarter. Moreover, several new product launches including VeriSeq NIPT Solution in Europe and launch of NovaSeq are contributing to the growth. Outside the U.S., the rate of NIPT adoption is increasing. The company’s reiterated guidance is encouraging indicating chances of rebound soon. We are also looking forward to GRAIL, Illumina’s venture in the cancer screening market. On the flip side, over the last three months, Illumina has been trading below the broader industry. Also, the company’s last reported first quarter was a mixed bag. While the bottom line was impacted by huge pressure on margins, strong top line growth was encouraging. Yet, tough competition and NIH funding issues continue to act as deterrants.”
  • 7/26/2017 – Illumina had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $170.00 price target on the stock.
  • 7/25/2017 – Illumina was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/19/2017 – Illumina had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $150.00 price target on the stock.
  • 7/10/2017 – Illumina had its “underweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $122.00 price target on the stock, up previously from $115.00.
  • 7/5/2017 – Illumina was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/3/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $197.84 price target on the stock.
  • 6/27/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $197.84 price target on the stock.
  • 6/24/2017 – Illumina was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/21/2017 – Illumina was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $197.84 price target on the stock.
  • 6/12/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $197.84 price target on the stock.

Shares of Illumina, Inc. (NASDAQ ILMN) traded down 2.30% on Thursday, hitting $194.65. 1,163,636 shares of the stock were exchanged. Illumina, Inc. has a one year low of $119.37 and a one year high of $199.95. The firm’s 50 day moving average price is $178.82 and its 200 day moving average price is $173.34. The firm has a market cap of $28.42 billion, a price-to-earnings ratio of 39.05 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter last year, the company earned $0.86 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post $3.65 earnings per share for the current year.

In other Illumina news, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $197.00, for a total transaction of $316,973.00. Following the transaction, the senior vice president now owns 9,037 shares of the company’s stock, valued at approximately $1,780,289. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total transaction of $2,561,550.00. Following the transaction, the director now directly owns 534,176 shares in the company, valued at approximately $91,221,235.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,010 shares of company stock worth $23,946,015. 1.60% of the stock is owned by corporate insiders.

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.